Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations.

PubWeight™: 2.66‹?› | Rank: Top 1%

🔗 View Article (PMID 18199519)

Published in J Hepatol on January 03, 2008

Authors

Jessica Tan1, Bulent Degertekin, Stephen N Wong, Munira Husain, Kelly Oberhelman, Anna S F Lok

Author Affiliations

1: Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI 48109-0362, USA.

Associated clinical trials:

A Korean Cohort Study of TDF Rescue Therapy for Difficult-to-treat CHB Patients: a Comparison Between TDF Monotherapy and TDF-based Combination Therapy | NCT02019966

Articles citing this

KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol (2012) 2.10

Liver transplantation outcomes among Caucasians, Asian Americans, and African Americans with hepatitis B. Liver Transpl (2009) 1.46

Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses? J Antimicrob Chemother (2008) 1.21

Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol (2009) 1.18

Th1 and Th2 immune response in chronic hepatitis B patients during a long-term treatment with adefovir dipivoxil. Mediators Inflamm (2010) 1.17

KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol (2016) 1.07

Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob Agents Chemother (2008) 0.99

Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovir. Antimicrob Agents Chemother (2012) 0.97

Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B. Therap Adv Gastroenterol (2010) 0.96

Efficacy and safety of tenofovir-based rescue therapy for chronic hepatitis B patients with previous nucleo(s/t)ide treatment failure. Gut Liver (2013) 0.95

Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade. Clin Mol Hepatol (2013) 0.94

Antiviral treatment of chronic hepatitis B virus (HBV) infections. Viruses (2010) 0.93

Update on hepatitis B virus infection. World J Gastroenterol (2014) 0.93

Complex dynamics of hepatitis B virus resistance to adefovir. Hepatology (2009) 0.92

Potency of tenofovir in chronic hepatitis B: mono or combination therapy? J Hepatol (2007) 0.91

Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues. World J Gastroenterol (2012) 0.90

Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C. Viruses (2010) 0.87

Management of antiviral drug resistance in chronic hepatitis B. World J Gastroenterol (2014) 0.85

Current and future directions for treating hepatitis B virus infection. World J Hepatol (2015) 0.85

Molecular diagnosis and treatment of drug-resistant hepatitis B virus. World J Gastroenterol (2014) 0.84

Tenofovir and its potential in the treatment of hepatitis B virus. Ther Clin Risk Manag (2009) 0.82

Current status of antiviral therapy for hepatitis B. Therap Adv Gastroenterol (2008) 0.81

Intracellular Activation of Tenofovir Alafenamide and the Effect of Viral and Host Protease Inhibitors. Antimicrob Agents Chemother (2015) 0.79

Comparative Meta-Analysis of Tenofovir Disoproxil Fumarate versus Emtricitabine and Tenofovir Disoproxil Fumarate as Treatments for Patients with Chronic Hepatitis B. Sci Rep (2015) 0.78

Does the presence of adefovir-resistant variants lead to failure of tenofovir monotherapy? J Hepatol (2008) 0.77

New approaches in the management of chronic hepatitis B: role of tenofovir. Infect Drug Resist (2009) 0.76

The Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide Analogs. J Clin Transl Hepatol (2014) 0.76

Pseudomonas exotoxin antisense RNA selectively kills hepatitis B virus infected cells. World J Gastroenterol (2008) 0.76

Is there Emergence of Clinical HBV Resistance Under Long-Term HBV Combination Therapy? A Challenging Case Report. Viruses (2010) 0.76

Genotyping and Mutation Pattern in the Overlapping MHR Region of HBV Isolates in Southern Khorasan, Eastern Iran. Hepat Mon (2016) 0.75

Comparison of the efficacy of tenofovir monotherapy versus tenofovir-based combination therapy in adefovir-experienced chronic hepatitis B patients: a systematic review and meta-analysis. Int J Clin Exp Med (2015) 0.75

Efficacy of Tenofovir-Based Combination Therapy versus Tenofovir Monotherapy in Chronic Hepatitis B Patients Presenting with Suboptimal Responses to Pretreatment: A Meta-Analysis. Gastroenterol Res Pract (2016) 0.75

Hepatitis B reactivation characterized by HBsAg negativity and anti-HbsAg antibodies persistence in haematopoietic stem cell transplanted patient after lamivudine withdrawal. BMC Infect Dis (2017) 0.75

Articles by these authors

Management of hepatitis B: summary of a clinical research workshop. Hepatology (2007) 3.40

Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35

Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology (2009) 3.10

Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology (2002) 2.79

Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol (2005) 2.63

Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology (2008) 2.44

Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B. J Hepatol (2010) 2.38

Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology (2003) 2.38

Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology (2002) 2.34

Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol (2005) 2.26

Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl (2002) 2.25

Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol (2003) 2.18

Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection? Hepatology (2004) 2.09

Noninvasive monitoring of patients with chronic hepatitis C. Hepatology (2002) 2.08

Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology (2006) 2.06

Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol (2005) 2.04

Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology (2011) 1.98

Impact of the model for end-stage liver disease allocation policy on the use of high-risk organs for liver transplantation. Gastroenterology (2008) 1.95

HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology (2002) 1.88

Re-weighting the model for end-stage liver disease score components. Gastroenterology (2008) 1.83

Clinical significance of hepatitis B virus genotypes. Hepatology (2002) 1.82

Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut (2010) 1.78

Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology (2006) 1.76

Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology (2006) 1.76

Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transpl (2008) 1.72

Presence of intrahepatic (total and ccc) HBV DNA is not predictive of HBV recurrence after liver transplantation. Liver Transpl (2007) 1.64

Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma. Liver Transpl (2007) 1.61

Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl (2007) 1.58

Indications for therapy in hepatitis B. Hepatology (2009) 1.57

When to start and stop hepatitis B treatment: can one set of criteria apply to all patients regardless of age at infection? Ann Intern Med (2007) 1.48

Chronic disease management for patients with cirrhosis. Gastroenterology (2010) 1.47

Prevalence of HBV precore/core promoter variants in the United States. Hepatology (2003) 1.47

Liver transplantation outcomes among Caucasians, Asian Americans, and African Americans with hepatitis B. Liver Transpl (2009) 1.46

Identification and management of hepatitis C patients in primary care clinics. Am J Gastroenterol (2003) 1.45

Serum ghrelin levels in inflammatory bowel disease with relation to disease activity and nutritional status. Dig Dis Sci (2007) 1.45

Rapid and sensitive assays for determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promoter variants. J Clin Microbiol (2003) 1.43

Clinical decisions. Management of incidental hepatitis C virus infection. N Engl J Med (2009) 1.42

Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology (2009) 1.35

Newer markers for hepatocellular carcinoma. Gastroenterology (2004) 1.31

Sensitivity and accuracy of an updated line probe assay (HBV DR v.3) in detecting mutations associated with hepatitis B antiviral resistance. J Hepatol (2008) 1.25

Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir. J Clin Microbiol (2006) 1.25

Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology (2012) 1.25

Emotional distress in chronic hepatitis C patients not receiving antiviral therapy. J Hepatol (2002) 1.19

Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol (2009) 1.18

Erosive esophagitis in the Philippines: a comparison between two time periods. J Gastroenterol Hepatol (2007) 1.14

HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. Hepatology (2006) 1.13

Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl (2007) 1.10

A genotype-independent real-time PCR assay for quantification of hepatitis B virus DNA. J Clin Microbiol (2006) 1.08

Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J Hepatol (2009) 1.06

Patient decision making about organ quality in liver transplantation. Liver Transpl (2011) 1.04

Management of hepatitis B patients with antiviral resistance. Antivir Ther (2004) 1.02

Outcomes of patients with chest tube insertion for hepatic hydrothorax. Hepatol Int (2009) 1.01

Report on a single-topic conference on "Chronic viral hepatitis--strategies to improve effectiveness of screening and treatment". Hepatology (2012) 1.00

Hepatitis B virus core promoter mutations contribute to hepatocarcinogenesis by deregulating SKP2 and its target, p21. Gastroenterology (2011) 1.00

Viral factors and outcomes of chronic HBV infection. Am J Gastroenterol (2011) 0.98

Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C. Clin Gastroenterol Hepatol (2008) 0.98

Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin Gastroenterol Hepatol (2008) 0.96

Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial. Clin Gastroenterol Hepatol (2010) 0.95

Emotional distress during interferon-alpha-2B and ribavirin treatment of chronic hepatitis C. Psychosomatics (2002) 0.95

Update on viral hepatitis: 2008. Curr Opin Gastroenterol (2009) 0.93

Effectiveness of interferon alpha-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practice. Clin Gastroenterol Hepatol (2004) 0.92

Management of patients with hepatitis B virus-induced cirrhosis. J Hepatol (2004) 0.91

Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C. Hepatology (2008) 0.91

Antiviral options for the treatment of chronic hepatitis B. J Antimicrob Chemother (2006) 0.91

Treatment of hepatitis B. J Gastroenterol (2002) 0.90

Monitoring antiviral resistance in patients receiving nucleos(t)ide analog therapies for hepatitis B: which method should be used? J Hepatol (2008) 0.89

Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C. Hepatology (2007) 0.89

[AASLD Practice Guidelines. Chronic hepatitis B: update of therapeutic guidelines]. Rom J Gastroenterol (2004) 0.88

Two distinct subtypes of hepatitis B virus-related acute liver failure are separable by quantitative serum immunoglobulin M anti-hepatitis B core antibody and hepatitis B virus DNA levels. Hepatology (2012) 0.88

Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C. Am J Gastroenterol (2008) 0.88

Treatment of chronic hepatitis B: who to treat, what to use, and for how long? Clin Gastroenterol Hepatol (2004) 0.88

Cognitive reserve and neuropsychological functioning in patients infected with hepatitis C. J Int Neuropsychol Soc (2007) 0.87

HBV core promoter mutations promote cellular proliferation through E2F1-mediated upregulation of S-phase kinase-associated protein 2 transcription. J Hepatol (2013) 0.87

Outcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting list. Clin Gastroenterol Hepatol (2007) 0.87

Drug insight: Nucleoside and nucleotide analog inhibitors for hepatitis B. Nat Clin Pract Gastroenterol Hepatol (2004) 0.87

Tenofovir disoproxil fumarate: role in hepatitis B treatment. Hepatology (2006) 0.86

Occult hepatitis B virus infection in patients with hepatocellular carcinoma: Innocent bystander, cofactor, or culprit? Gastroenterology (2004) 0.85

Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial. Hepatology (2011) 0.85

Does antiviral therapy prevent recurrence of hepatitis B virus–related hepatocellular carcinoma after curative liver resection? JAMA (2012) 0.85

Long-term efficacy of nucleoside monotherapy in preventing HBV infection in HBsAg-negative recipients of anti-HBc-positive donor livers. Hepatol Int (2010) 0.83

Hepatitis B virus genotypes, precore and core promoter variants among predominantly Asian patients with chronic HBV infection in a Canadian center. Liver Int (2006) 0.81

Is family history of liver cancer a risk factor for hepatocellular carcinoma? J Hepatol (2008) 0.81

Impact of the hepatitis B virus genotype on pre- and post-liver transplantation outcomes. Liver Transpl (2008) 0.81

Update on viral hepatitis: 2005. Curr Opin Gastroenterol (2006) 0.81

The dawn of a new era: transforming our domestic response to hepatitis B & C. Gastroenterology (2010) 0.81

Clinical outcomes of liver transplantation for HBV-related hepatocellular carcinoma: data from the NIH HBV OLT study. Clin Transplant (2010) 0.81

A Burkitt's Lymphoma Case Mimicking Crohn's Disease: A Case Report. Case Rep Med (2011) 0.79

Hepatitis C disease severity in living versus deceased donor liver transplant recipients: an extended observation study. Hepatology (2014) 0.78

Combination of HBIG and lamivudine-resistant mutations: a formula for trouble? Liver Transpl (2002) 0.78

Treatment of hepatocellular carcinoma using internally cooled electrodes. A prospective comparison of modified automated vs. manual pulsed radiofrequency algorithms. Oncology (2007) 0.78

Viral hepatitis at a crossroad. Gastroenterology (2012) 0.77

Update on viral hepatitis in 2004. Curr Opin Gastroenterol (2005) 0.77

Treatment of hepatitis B: who, when, and how? Arch Intern Med (2006) 0.77